Please provide your email address to receive an email when new articles are posted on . The phase 2 DR:EAM clinical trial did not meet the endpoint of the percentage of patients with a two-step or ...

According to the phase II/III DIAMOND trial, there was early evidence of efficacy for OCS-01 eye drops in patients with diabetic macular edema (DME) compared with sham. The findings were reported at ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN FRANCISCO -- ...

Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announced the data from a successful Phase Ib/IIa ...

Roughly 55 percent of Medicaid enrollees are working full or part time, and a number aren’t eligible for health insurance ...

Please provide your email address to receive an email when new articles are posted on . SAN FRANCISCO — An eye drop improved visual acuity in patients with diabetic macular edema, according to a study ...

TOKYO, Feb. 6, 2024 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announced the enrollment of the first patient in a Phase 2 clinical trial, multi-center, randomized, double-masked, parallel ...

DIAMOND trial in Diabetic Macular Edema (DME) with topical OCS-01 met its stage 1 objective of validating the loading and maintenance dosing regimen designed to optimize OCS-01 efficacy potential with ...

A widely prescribed type of medication for the management of type 2 diabetes may also help reduce the risk of developing an eye condition that can lead to vision loss. The researchers said that people ...

Diabetic eye disease is the leading cause of blindness among people ages 40 to 60. The longer you have diabetes, the greater your likelihood of developing vision problems increases. Keeping blood ...

CAMBRIDGE, England & NOTTINGHAM, England--(BUSINESS WIRE)--Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases ...